Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe ...

The Lupus Foundation of America describes lupus as a chronic disease that attacks the immune system, the part of the body ...

Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Medicare covers lupus treatment in different ways depending on your age and how the condition affects you. Read more.

Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disorder characterized by a diverse spectrum of clinical manifestations. Although survival rates among patients with SLE have ...

A common form of lupus is systemic lupus erythematosus. Systemic lupus erythematosus affects the whole body and can attack virtually any part of it, including skin, major organs, hair, muscles ...

Systemic lupus erythematosus, or lupus, is a complex autoimmune disease ... particularly promising led to visible improvements in a clinical study in patients with cutaneous lupus after just two weeks ...

Werth V, et al. Efficacy and safety of oral deucravacitinib in patients with cutaneous manifestations of lupus erythematosus: Results from PAISLEY CLE, a global, phase 2 randomized, double-blind ...

In a small phase II trial of cutaneous lupus erythematosus (CLE), patients treated with the TYK2 inhibitor had as much as 50% improvement in disease status at week 16. Adverse events in both ...